Event : Cardiovascular Safety and State-of-the-art Development Issues: Type 2 Diabetes Mellitus Medications, QT, Benefit/Risk Assessment, Arrhythmias, Thrombosis, and Cardiotoxicity http://www.rsc.org/events/detail/7321/Cardiovascular%20Safety%20and%20State-of-the-art%20Development%20Issues%3a%20Type%202%20Diabetes%20Mellitus%20Medications%2c%20QT%2c%20Benefit/Risk%20Assessment%2c%20Arrhythmias%2c%20Thrombosis%2c%20and%20Cardiotoxicity This is a feed for event : Cardiovascular Safety and State-of-the-art Development Issues: Type 2 Diabetes Mellitus Medications, QT, Benefit/Risk Assessment, Arrhythmias, Thrombosis, and Cardiotoxicity Thu, 11 Sep 2014 13:13:13 +0100 7321 7321 http://www.rsc.org/events/detail/7321/Cardiovascular%20Safety%20and%20State-of-the-art%20Development%20Issues%3a%20Type%202%20Diabetes%20Mellitus%20Medications%2c%20QT%2c%20Benefit/Risk%20Assessment%2c%20Arrhythmias%2c%20Thrombosis%2c%20and%20Cardiotoxicity Cardiovascular Safety and State-of-the-art Development Issues: Type 2 Diabetes Mellitus Medications, QT, Benefit/Risk Assessment, Arrhythmias, Thrombosis, and Cardiotoxicity Event dates: 17 - 18 April 2012<br/>Event summary: Join Industry Experts and Regulators to Improve Your Safety Analysis During Drug Development, Analyze and Mitigate Potential Risks, and Explore New Solutions and Approaches to Developing Safe and Ef<br/>Event Venue: Washington Marriott Hotel, Washington, DC, 20037, United States Thu, 11 Sep 2014 13:13:13 +0100 2014-09-11T13:13:13+01:00